

To:	BHS Narcotic Treatment Program (NTP) Contracted Service Providers
From:	Behavioral Health Services
Date:	October 13, 2026
Title	Brixadi Injectable Now Available for NTP Billing

Brixadi is an injectable buprenorphine medication to help decrease opioid use. California's Department of Health Care Services (DHCS) indicated that during the August 11th System Change deployment, the SD/MC system has been updated to include monthly Brixadi forms under Drug Type 9. This update expands the Medication-Assisted Treatment (MAT) options available for treating opioid addiction in NTP settings. Claims submitted after this date using Monthly Brixadi National Drug Codes (NDCs) will be allowed and reimbursed at the current Buprenorphine Injectable Monthly Rate. The weekly rate is pending DHCS review and providers will be notified once available. Please find the Brixadi NDCs added to the system below.

NDC_Code_Id	NDC_Code	Drug_Name	Labeler_Name	ADP_Drug_Type_Id	Effective_From_Date
1073	58284026401	BRIXADI MONTHLY 64MG/0.18 ML SYRINGE	BUPRENORPHINE	9	6/6/2023
1074	58284029601	BRIXADI MONTHLY 96MG/0.27 ML SYRINGE	BUPRENORPHINE	9	6/6/2023
1075	58284022801	BRIXADI MONTHLY 128MG/0.36 ML SYRINGE	BUPRENORPHINE	9	6/6/2023

Brixadi NDCs will be available to select on the procedure drop down. The procedure codes are set up in SmartCare: S5000 (generic) / S5001 (brand).

For More Information, contact:

- Your Contracting Officer's Representative (COR)
- Fiscal: SFBudget.BHS1@sdcounty.ca.gov
- Billing: SUDBillingUnit.BHS@sdcounty.ca.gov
- MIS: BHS_EHRSupport.HHSA@sdcounty.ca.gov
- QI: QIMatters.HHSA@sdcounty.ca.gov